VRAX

$0.00

(

0.00%

)
Quote details

stock

Virax Biolabs Group Limited Ordinary Shares

NASDAQ | VRAX

0.63

USD

$0.00

(

0.00%

)

AT CLOSE (AS OF Aug 26, 2025)

$3.36M

MARKET CAP

-

P/E Ratio

-1.62

EPS

$7.63

52 Week High

$0.72

52 Week Low

LIFE SCIENCES

Sector

VRAX Chart

Recent Chart
Price Action

VRAX Technicals

Tags:

VRAX Earnings

Yearly Income Statement (As of Mar 31, 2025)

Field Value (USD)
Gross Profit -$53K
Total Revenue $6.3K
Cost Of Revenue $59K
Costof Goods And Services Sold $59K
Operating Income -$6.2M
Selling General And Administrative $4.3M
Research And Development $1.8M
Operating Expenses $6.1M
Investment Income Net -
Net Interest Income -$58K
Interest Income -
Interest Expense $58K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $343K
Income Before Tax -$6.2M
Income Tax Expense -$137K
Interest And Debt Expense -
Net Income From Continuing Operations -$6.1M
Comprehensive Income Net Of Tax -
Ebit -$6.1M
Ebitda -$5.8M
Net Income -$6.1M

Revenue & Profitability

Earnings Performance

VRAX Financials

yearly Balance Sheet (As of Mar 31, 2025)

Field Value (USD)
Total Assets $6.4M
Total Current Assets $4.9M
Cash And Cash Equivalents At Carrying Value $4.2M
Cash And Short Term Investments $4.2M
Inventory $95K
Current Net Receivables $31K
Total Non Current Assets $1.5M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $539K
Other Non Current Assets -
Total Liabilities $965K
Total Current Liabilities $673K
Current Accounts Payable $56K
Deferred Revenue -
Current Debt -
Short Term Debt $85K
Total Non Current Liabilities $292K
Capital Lease Obligations $345K
Long Term Debt -
Current Long Term Debt $32K
Long Term Debt Noncurrent -
Short Long Term Debt Total $377K
Other Current Liabilities $525K
Other Non Current Liabilities -
Total Shareholder Equity $5.7M
Treasury Stock -
Retained Earnings -$25M
Common Stock $4.3K
Common Stock Shares Outstanding $3.1M

yearly Cash Flow (As of Mar 31, 2025)

Field Value (USD)
Operating Cashflow -$4.6M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $343K
Capital Expenditures $604K
Change In Receivables -
Change In Inventory -$34K
Profit Loss -
Cashflow From Investment -$604K
Cashflow From Financing $5.8M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$6.1M

yearly Income Statement (As of Mar 31, 2025)

Field Value (USD)
Gross Profit -$53K
Total Revenue $6.3K
Cost Of Revenue $59K
Costof Goods And Services Sold $59K
Operating Income -$6.2M
Selling General And Administrative $4.3M
Research And Development $1.8M
Operating Expenses $6.1M
Investment Income Net -
Net Interest Income -$58K
Interest Income -
Interest Expense $58K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $343K
Income Before Tax -$6.2M
Income Tax Expense -$137K
Interest And Debt Expense -
Net Income From Continuing Operations -$6.1M
Comprehensive Income Net Of Tax -
Ebit -$6.1M
Ebitda -$5.8M
Net Income -$6.1M

VRAX News

VRAX Profile

Virax Biolabs Group Limited Ordinary Shares Profile

Sector: LIFE SCIENCES

Industry: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

Virax Biolabs Group Limited, a biotechnology company, sells, distributes and markets diagnostic test kits and medical technology products and PPE for the prevention, detection, diagnosis and risk management of viral diseases in the field of immunology. The company is headquartered in London, the United Kingdom.

IXHL
-5.50%
$0.69
ALLR
+55.21%
$1.46
CGBS
-39.47%
$0.03
TNFA
+13.72%
$0.07
IVVD
+84.02%
$1.03
HKPD
+35.23%
$1.42
NIO
+9.93%
$6.69
TLRY
+3.95%
$1.44
NVDA
+1.13%
$181.84
EPIX
-66.43%
$0.26
BENF
+7.32%
$0.41
PFSA
-16.06%
$0.41
PLTR
+2.35%
$160.87
AIFF
+4.63%
$2.71
RR
+32.76%
$3.15
LCID
+1.68%
$2.11
DNN
+6.49%
$2.21
TSLA
+1.46%
$351.67
INTC
-0.81%
$24.35
WBA
-0.35%
$11.92
TPIC
-45.91%
$0.12
SOUN
-0.74%
$12.02
AXDX
-61.36%
$0.03
SOFI
-2.31%
$25.54
AAL
+1.15%
$13.15
STKH
+22.76%
$0.66
SNAP
-2.77%
$7.00
KDP
-6.63%
$29.03
LYT
-16.77%
$0.09
AMD
+1.99%
$166.62
F
+0.12%
$11.83
AAPL
+0.94%
$229.31
OPAD
+2.47%
$3.73
RIVN
+0.15%
$13.11
MRKR
-20.63%
$1.01
NUKK
+17.40%
$5.80
MARA
+3.51%
$15.94
ONDS
+1.99%
$4.94
SATS
+71.10%
$51.12
BMNR
+1.10%
$50.14
ATNF
-6.81%
$3.07
RMBL
+60.50%
$3.21
RGTI
+5.73%
$15.30
ADD
-25.47%
$0.05
PLUG
-1.19%
$1.65
BAC
+1.51%
$50.23
VHAI
0.00%
$0.00
SRM
+53.27%
$10.30
ETHD
-6.60%
$3.25
JOBY
+2.65%
$14.68
WULF
+3.46%
$9.23
RAYA
-10.20%
$0.04
IQ
-2.48%
$2.35
ITUB
-0.94%
$6.80
BBD
-0.50%
$2.98
RIOT
+2.03%
$13.55
ABEV
0.00%
$2.20
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
MSFT
-0.44%
$502.04
WLGS
-5.57%
$0.04
GPRO
+6.36%
$1.75
GOOGL
-0.64%
$207.14
CVE
+0.14%
$16.72
T
-0.99%
$28.45
CGC
+1.61%
$1.46
KEY
+1.49%
$19.30
ETWO
0.00%
$3.30
AUR
-2.18%
$5.82
TME
+1.94%
$26.22
WBD
-0.95%
$11.92
AVGO
+1.28%
$298.01
ADAP
+7.20%
$0.06
OKLO
+4.39%
$74.31
VRAX
-18.17%
$0.63
APLD
-0.62%
$15.95
CIFR
+5.83%
$7.02
AFMD
-34.94%
$0.18
SBET
+4.25%
$19.98
QBTS
+2.79%
$15.44
RKLB
+2.23%
$48.27
HIMS
+5.71%
$45.44
PTHL
+14.90%
$0.64
UP
+26.40%
$3.02
WMT
-0.05%
$96.02
CSX
-1.50%
$32.31
PFE
-0.79%
$24.94
HL
+1.71%
$7.99
AMCR
-2.06%
$8.52
BTBT
+1.07%
$2.81
HOOD
+0.12%
$108.07
RF
+1.66%
$27.09
RAY
-20.12%
$2.50
NOK
-1.38%
$4.28
CRML
+9.04%
$6.87
SMCI
+0.43%
$44.07
UUUU
+3.30%
$10.93
IREN
-1.07%
$22.87
IBIO
-9.06%
$0.76
BTG
+2.14%
$4.03
IXHL
-5.50%
$0.69
ALLR
+55.21%
$1.46
CGBS
-39.47%
$0.03
TNFA
+13.72%
$0.07
IVVD
+84.02%
$1.03
HKPD
+35.23%
$1.42
NIO
+9.93%
$6.69
TLRY
+3.95%
$1.44
NVDA
+1.13%
$181.84
EPIX
-66.43%
$0.26
BENF
+7.32%
$0.41
PFSA
-16.06%
$0.41
PLTR
+2.35%
$160.87
AIFF
+4.63%
$2.71
RR
+32.76%
$3.15
LCID
+1.68%
$2.11
DNN
+6.49%
$2.21
TSLA
+1.46%
$351.67
INTC
-0.81%
$24.35
WBA
-0.35%
$11.92
TPIC
-45.91%
$0.12
SOUN
-0.74%
$12.02
AXDX
-61.36%
$0.03
SOFI
-2.31%
$25.54
AAL
+1.15%
$13.15
STKH
+22.76%
$0.66
SNAP
-2.77%
$7.00
KDP
-6.63%
$29.03
LYT
-16.77%
$0.09
AMD
+1.99%
$166.62
F
+0.12%
$11.83
AAPL
+0.94%
$229.31
OPAD
+2.47%
$3.73
RIVN
+0.15%
$13.11
MRKR
-20.63%
$1.01
NUKK
+17.40%
$5.80
MARA
+3.51%
$15.94
ONDS
+1.99%
$4.94
SATS
+71.10%
$51.12
BMNR
+1.10%
$50.14
ATNF
-6.81%
$3.07
RMBL
+60.50%
$3.21
RGTI
+5.73%
$15.30
ADD
-25.47%
$0.05
PLUG
-1.19%
$1.65
BAC
+1.51%
$50.23
VHAI
0.00%
$0.00
SRM
+53.27%
$10.30
ETHD
-6.60%
$3.25
JOBY
+2.65%
$14.68
WULF
+3.46%
$9.23
RAYA
-10.20%
$0.04
IQ
-2.48%
$2.35
ITUB
-0.94%
$6.80
BBD
-0.50%
$2.98
RIOT
+2.03%
$13.55
ABEV
0.00%
$2.20
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
MSFT
-0.44%
$502.04
WLGS
-5.57%
$0.04
GPRO
+6.36%
$1.75
GOOGL
-0.64%
$207.14
CVE
+0.14%
$16.72
T
-0.99%
$28.45
CGC
+1.61%
$1.46
KEY
+1.49%
$19.30
ETWO
0.00%
$3.30
AUR
-2.18%
$5.82
TME
+1.94%
$26.22
WBD
-0.95%
$11.92
AVGO
+1.28%
$298.01
ADAP
+7.20%
$0.06
OKLO
+4.39%
$74.31
VRAX
-18.17%
$0.63
APLD
-0.62%
$15.95
CIFR
+5.83%
$7.02
AFMD
-34.94%
$0.18
SBET
+4.25%
$19.98
QBTS
+2.79%
$15.44
RKLB
+2.23%
$48.27
HIMS
+5.71%
$45.44
PTHL
+14.90%
$0.64
UP
+26.40%
$3.02
WMT
-0.05%
$96.02
CSX
-1.50%
$32.31
PFE
-0.79%
$24.94
HL
+1.71%
$7.99
AMCR
-2.06%
$8.52
BTBT
+1.07%
$2.81
HOOD
+0.12%
$108.07
RF
+1.66%
$27.09
RAY
-20.12%
$2.50
NOK
-1.38%
$4.28
CRML
+9.04%
$6.87
SMCI
+0.43%
$44.07
UUUU
+3.30%
$10.93
IREN
-1.07%
$22.87
IBIO
-9.06%
$0.76
BTG
+2.14%
$4.03

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.